FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2449-2451 June 9, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reyes, F. PubMed Citation

To the Editor: Reyes and colleagues (March 24 issue)¹ should elaborate on the disadvantages, particularly the long-term side effects, of a regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) in comparison with a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). With an increased duration of parenteral chemotherapy (20, rather than 3, days), ACVBP has a complicated schedule and thus poses a compliance problem in nonresearch settings. Furthermore, in many centers, patients need hospitalization to ensure hydration during high-dose methotrexate therapy. ACVBP also causes more mucositis, neutropenia, and thrombocytopenia than does CHOP, and it increases the risk of myelodysplasia . . . [Full Text of this Article]

This article has been cited by other articles:

• Gemici, C., Salepci, T. (2007). How Can We Determine the Role of Radiotherapy in the Treatment of Localized Aggressive Non-Hodgkin's Lymphoma?. JCO 25: 2857-2857 [Full Text]